

PRINCIPLES OF DONOR PLATELET APHERESIS

Fevzi Altuntas, MD
European Society For
Hemapheresis Congress
2-6 October 2005

What is an Apheresis Donation?

- Apheresis involves the use of machines to selectively collect a blood component (red cells, platelets, white cells or plasma).
- A specific blood component is selected and is automatically separated by the machine (most commonly platelets or plasma).
- The components that are not required are returned to the donor.
- The advantage of an apheresis donation is that relatively large amounts of the component can be selectively collected.

What are Platelets?

- Platelets are colorless, irregularly shaped bodies found in blood.
- The primary role of platelets is to prevent bleeding in injured blood vessel walls by forming an aggregate at the site of injury.
- Platelets can also participate in blood coagulation, inflammation and wound healing.

Who can Donate Blood

Age:	17 th – 71 st birthday (regular donor) 17 th – 61 st birthday (first time donor)
Weight:	At least 50 kg (110 lbs)
Hemoglobin:	Must meet requirements
Frequency of Donation:	Minimum interval between donations is 56 days
Health:	In good health and feeling well.
Screening:	At time of donation, a number of questions are asked to determine donor eligibility, e.g.:

If donor has had a

- ***Dentist visit:***
- ***Cold, flu or sore throat:***
- ***Ear/ body piercing or tattooing:***

Donor must wait before donating for...

3 days after visit
Full recovery
6 months

Why are Single Donor Apheresis Products Requested?


Platelets:

- To prevent alloimmunization (e.g., bone marrow transplantation).
- For refractory patients, HLA/platelet antigen matched for patients with specific HLA/platelet antibodies.
- For directed donations, e.g., mother to baby for neonatal thrombocytopenia (NTP).

Principles of apheresis


Anticoagulant
added

Remaining blood components
recombined and returned



APHERESIS PROCEDURES - GENERAL

- Used for treatment or blood component donation
- Allows blood separation at bedside
- < 15% of blood volume in extracorporeal circuit
- Sterile, single use tubing and separation kit
- Anticoagulant must be added - usually citrate (ACD)




Apheresis Methods


- Filtration

- Plasma only
- Europe and Japan
- Specialized U.S. procedures
- Smaller equipment, smaller extracorporeal volume

- Centrifugation

- Most versatile
- Any cell or plasma can be removed
- Popular in U.S.
- Larger equipment and larger extracorporeal volume







APHERESIS TECHNOLOGY

(centrifugal)

- Continuous flow
 - One or two access points
 - Continuous blood separation
- Intermittent flow
 - One access needed
 - Blood separation in cycles
 - Slightly longer processing time
 - Slightly larger extracorporeal volume

A decorative graphic on the left side of the slide, consisting of a light green vertical bar and a white rounded rectangle with a green border. A thick dark blue horizontal bar spans across the top of the white area.

DONOR APHERESIS

APHERESIS DONOR COLLECTIONS

- Platelets
- Plasma
- Granulocytes
- Red blood cells
- Lymphocytes
- Peripheral blood stem cells

Donor Apheresis

- Advantages

- Select only component(s) needed
- Return rest of blood
- No need for component separation in lab
- More frequent donation allowed (some)

- Disadvantages

- Expense/equipment/training
- Citrate exposure


Donor Apheresis

- Probable trend in future
- May totally replace whole blood donation
- Can customize collection:
 - -Individual donor preferences
 - -Blood type of donor
 - -Inventory needs of blood center


DONOR APHERESIS EQUIPMENT - U.S., 2002

- Continuous Flow
- Baxter/Fenwal CS-3000 Plus, Amicus
- Gambro/Cobe Spectra, Trima
- Intermittent Flow
- Haemonetics LN-8150 MCS, LN-9000 MCS






TRIMA Accel



Automated Blood Component Collection System

2 - 3 Transfusions



COMPLICATIONS - DONOR APHERESIS

- Common
- Citrate toxicity
- Hematoma or infiltration
- Rare
- Allergy (citrate, plasticizer)
- Cellulitis
- Thrombosis
- Change in volume status

CITRATE

- Chelates calcium
- Metabolized in liver, kidney and skeletal muscle
- Cleared quickly from circulation
- Administered as ACD

SIGNS/SYMPTOMS OF CITRATE TOXICITY

- Tingling/numbness around nose and mouth "circumoral parasthesias"
- More extensive tingling
- Muscle cramping
- Vibration in chest
- Nausea
- Tetany
- Chvostek's sign


TREATMENT - CITRATE TOXICITY


- Mild cases:
- Tums
 - Milk
 - Slow procedure
 - Decrease ratio of anticoagulant to blood
- No bleeding tendency
- Much anticoagulant removed in platelet collection
- Severe cases -- IV calcium replacement


A decorative graphic on the left side of the slide, consisting of a light green vertical bar and a white rounded rectangle with a green border. A thick dark blue horizontal bar is positioned above the title.

PLATELET APHERESIS

Available Platelet Preparations








Platelet
Rich
Plasma

RBCs
and
WBCs



Platelets
and
Plasma



Plasma

Platelets



Most Plasma
Removed

Platelet
Concentrate



DONOR ELIGIBILITY - PLATELET APHERESIS

- No whole blood donation for 8 weeks
- No platelet donation for 48 hours
- No aspirin in last 36 hours
- Platelet count >150,000/ul
- No more than 2 times per week
- No more than 24 donations in one year

PLATELET COUNT- PLATELET APHERESIS

- Platelet count drops 25-35% after procedure
- Rarely below 90,000
- No bleeding complications
- Recovers in several days

APHERESIS QUALITY CONTROL

- Platelets:
 - $\geq 3.0 \times 10^{11}$ platelets per collection (90%)
 - pH ≥ 6.2 at 5 days (90%)
 - May check at issue if none available at 5 days
 - Test at least 4 per month:
 - Site, manufacturer, split vs single
- Granulocytes:
 - $\geq 1.0 \times 10^{10}$ WBCs per collection (75%)

SPLIT APHERESIS PLATELETS

- Donor with high platelet count
- Slightly longer procedure
- Yields bag of equal to or greater than 6.5×10^9 platelets
- Split immediately into two or three "doses"



Collection Date 490 5892
7-7-97

PLATELETS
PHERESIS

135 mL containing
approx 12.5 mL of
ADP Anticoagulant
Store at 20° to 24° C

See circular of information for
indications, contraindications,
cautions and methods of infusion.

VOLUNTEER DONOR

The product may transmit infectious agents.
Caution: Federal law prohibits dispensing without a
prescription.

PROPERLY IDENTIFY INTENDED RECIPIENT

12010

Rh POSITIVE

0

Collected and Processed by
BLOODCARE
Dallas, Texas 75238

Registration # 1871264



Collection Date 490 5892
7-7-97

PLATELETS
PHERESIS

135 mL containing
approx 12.5 mL of
ADP Anticoagulant
Store at 20° to 24° C

See circular of information for
indications, contraindications,
cautions and methods of infusion.

VOLUNTEER DONOR

The product may transmit infectious agents.
Caution: Federal law prohibits dispensing without a
prescription.

PROPERLY IDENTIFY INTENDED RECIPIENT

12010

Rh POSITIVE

0

Collected and Processed by
BLOODCARE
Dallas, Texas 75238

Registration # 1871264

APHERI
BLOO

PLATELET UNIT COUNTING

- QC for count and pH (4 per month)
- Also must count every bag
- Not required to label bag with count
- Low count bags must be so labeled

LEUKOREDUCTION AND PLATELET APHERESIS

- Gambro/Cobe - LRS system for Spectra and Trima
- Fenwal - Amicus with elutriation
- Haemonetics - Filter in MCS kit

fusion




ADVANTAGES – LEUKOREDUCTION IN APHERESIS

- Leukoreduction prior to storage
- No filter failure
- No loss of cells in filter
- Possible cost advantage

CONTAMINATION LEUKOCYTE LEVEL - QUALITY CONTROL

- WBCs $< 5.0 \times 10^9$ routinely
- WBCs $< 5.0 \times 10^6$ to be "leukoreduced"
- Europe and proposed U.S. 1.0×10^6
- Must count 4 per month per each site and technology (singles, doubles, and triples)



HAEMONETICS

MCS+

PRIME START RETURN STOP

Flow

100% Plasma

100% RBCs

100% WBCs

100% Platelets

100% Fibrinogen

100% Cryoprecipitate

100% Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Fibrinogen

100% Cryoprecipitate Depleted Plasma with Factor VIII

100% Cryoprecipitate Depleted Plasma with Factor VIII and Fibrinogen

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma


100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma


100% Cryoprecipitate Depleted Plasma with Factor VIII, Fibrinogen, and Thrombin and Cryoprecipitate Depleted Plasma and Cryoprecipitate Depleted Plasma

MCS+



APHERESIS COMPONENTS WITH SAME NUMBER

- Double RBC collections
- Double platelet collections
- Aliquots of jumbo plasma



Centrifuge speed	4800 – 7000 rpm (varies with protocol)
Pump speed	0-150 ml/min (adjustable)

TO YOUR APHERESIS PROGRAM.

For detailed information describing intended use, warnings, precautions and contraindications, refer to the instructions provided for each device or contact Haemonetics Corporation.



HAEMONETICS®

Apheresis Procedure Length

- Red cells plus plasma -- 40 minutes
- Double red blood cells -- 45 minutes
- Platelets (single) -- 70 to 120 minutes
- Granulocytes -- 3 hours
- Peripheral blood stem cells -- 4 to 6+ hours

Platelets Pheresis

- Hemapheresis is used to harvest a therapeutic adult dose of platelets from one individual donor
- Contains $> 3 \times 10^{11}$ platelets
- Equivalent of 6-8 units of platelets
- Leukocytes reduced

PLATELET PACKS: SINGLE DONOR

- Indications
 - Thrombocytopenia (<50,000/microL)
 - Cancer patients having chemo. or radiation (<20,000)
 - DIC (<50,000)
 - Massive transfusion (<50,000)
- If patient becomes refractory to plts (has plt Abs), will need to give single donor packs (plateletpheresis units)
 - determine 1 hr post transfusion plt increment (see p. 347)
 - if less than 50% of expected two times, pt. considered refractory
- ABO/Rh compatible

PLATELET PACKS: SINGLE DONOR

- Processing - requires special equipment to perform apheresis procedure
- At least 3×10^{11} plts in 300 mL
- Storage at RT with constant agitation for 5 days
- Indications - same as for random donor packs but patient has been shown to be refractory
- Expected net gain - 30,000 to 60,000/microL
- ABO/Rh compatible; may also type to determine HLA compatibility

Haemoglobin Testing



Bacterial Detection of Platelet Products

- AABB requirement since 3/04
- Two commercial systems detecting
 - CO₂ generation
 - O₂ consumption
- Swirling or pH

Documentation
Maintenance
Calibration
Labeling
of Platelet

DOCUMENTATION


Documents

- **approved information that describes the organisation's quality system policies, processes and procedures**
- **mostly SOPs eg. PLT preparation**

Records

- **capturing process/ procedure data on forms eg. PLT log**

Quality System Documentation Heirarchy



I POLICY DOCUMENTS

what will be done

II PROCESS DESCRIPTION DOCUMENTS

how it happens

III PROCEDURE DOCUMENTS

how to do it

IV RECORDS *what was done*

Documentation

Component preparation

General rules remain

Blood collection

- type of bags

- **Time**

- collection time

- bet' collection and separation

- time of storage

Separation

- centrifuge

- centrifugation time and speed

Platelet concentrate (RDP) Quality Control

Facility Name _____

Date _____

<i>Centrifuge #</i>	<i>Donor #</i>	<i>Expiration date</i>	<i>Volume 40-60 ml</i>	<i>pH > 6.2</i>	<i>Platelet count</i>	<i>Total plts per unit >5.5 x10¹⁰</i>	<i>Results Acceptable? Yes/No</i>	<i>Date tested</i>	<i>Tech</i>

Total % units meeting requirements

pH __ (100%)

Volume __ (100%)

Plt count __ (>75%)

Comments _____

Reviewed by _____ Date _____

SOP/ version date

MAINTENANCE

Equipment maintenance



Requirements of installation

- Installation validation
- Preventive maintenance -
AMC
- Regular calibration,
and after repairs
- Performance monitoring

RECORDS OF EQUIPMENT MAINTENANCE

- ***Instrument serial #*** _____
- ***Model no.*** _____
- ***Date of purchase*** _____
- ***Name of supplier*** _____
- ***Maintenance visit schedule*** _____
- ***Dates of breakdown / repairs*** _____

Signature _____

CALIBRATION

**Establishment of accuracy over operating range
by appropriate reference material/ calibrators**

**All calibrated equipment
label with**

- date of last calibration and signature**
- date of next calibration**

CALIBRATION

PERFORMANCE CHECKS

To verify that instrument in specified range of accuracy and precision

REFERENCE STANDARDS

Measurement standards

- Certificate of assigned values

Traceable to national standard of measurement

- Precalibrated certified stds.
- Internal working std.

RECORDS OF CALIBRATION

- ***Instrument serial #*** _____
- ***Date of calibration*** _____
- ***Due date of next calibration*** _____
- ***Details of adjustment/repairs*** _____
- ***Results of calibration*** _____
before/after repairs _____
- ***Statement of compliance*** _____

Signature _____

LABELING

Critical material in document management system

- **Must conform to regulatory requirements**
- **Quality supervisors must review/ approve before use**
- **Specific and controlled- size, type, wording**
- **Bar coded labels**
ISBT 128 : information, wording, location stdzed
enhances efficacy, accuracy & safety
- **Master set, careful when change out of old stock**
- **Special labeling e.g. irradiated or LD product**



THANK YOU